Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) and Biofrontera (NASDAQ:BFRI – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.
Institutional and Insider Ownership
27.9% of Eton Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.1% of Biofrontera shares are owned by institutional investors. 16.5% of Eton Pharmaceuticals shares are owned by company insiders. Comparatively, 8.1% of Biofrontera shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Volatility and Risk
Eton Pharmaceuticals has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, Biofrontera has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500.
Profitability
This table compares Eton Pharmaceuticals and Biofrontera’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Eton Pharmaceuticals | 12.02% | 40.13% | 12.37% |
| Biofrontera | -13.78% | -145.81% | -31.30% |
Analyst Ratings
This is a summary of current ratings for Eton Pharmaceuticals and Biofrontera, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Eton Pharmaceuticals | 0 | 1 | 4 | 1 | 3.00 |
| Biofrontera | 1 | 1 | 1 | 0 | 2.00 |
Eton Pharmaceuticals presently has a consensus price target of $71.50, indicating a potential upside of 43.00%. Given Eton Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Eton Pharmaceuticals is more favorable than Biofrontera.
Earnings and Valuation
This table compares Eton Pharmaceuticals and Biofrontera”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Eton Pharmaceuticals | $105.59 million | 13.53 | -$4.60 million | $0.38 | 131.58 |
| Biofrontera | $41.71 million | 0.28 | -$10.54 million | ($0.45) | -1.75 |
Eton Pharmaceuticals has higher revenue and earnings than Biofrontera. Biofrontera is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Eton Pharmaceuticals beats Biofrontera on 15 of the 15 factors compared between the two stocks.
About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
About Biofrontera
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
